Labetalol, an alpha‐ and beta‐adrenoceptor‐blocking agent: its use in therapeutics. A summary of the symposium.

Prichard, B. N. C.; Richards, DA

doi:10.1111/j.1365-2125.1979.tb04788.x

Cited by 9 publications

(2 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Labetalol is an antihypertensive agent with both non-selective pand a-blocking properties (6). Using this compound, the aim of the present study was to further clarify the Abbreuiations: FSP = finger systolic pressure, FSP%= percentage of control FSP at 30°, ANF = antinuclear factor.…”

Section: Words: Uasoconstriction Adrenergic /$Receptor Blockers A-rmentioning

confidence: 97%

Raynaud's Phenomenon Caused by β‐Receptor Blocking Drugs

Eliasson

Danielson

Hylander

et al. 1984

Journal of Internal Medicine

View full text Add to dashboard Cite

Twenty‐four hypertensive patients reported vasospastic symptoms in their hands during treatment with β‐blocking drugs with different pharmacological properties. Twenty patients had symptoms when staying indoors and 11 did not always experience complete relief of symptoms following active rewarming attempts. Finger systolic blood pressures were measured after standardized local cooling. In 15 patients, blood pressure decreased to a pathological level during this procedure. Previous β‐blockade was changed to combined α‐ and β‐blockade with labetalol given twice daily in a mean dose of 259 mg/day for 3 months. After this period, most patients showed a decreased temperature sensitivity both objectively and subjectively. Blood pressure control was maintained at the previous level. Heart rate increased significantly during treatment with labetalol. Labetalol offers an alternative treatment to patients suffering from vasospastic side‐effects of β‐blockers.

show abstract

Section: Words: Uasoconstriction Adrenergic /$Receptor Blockers A-rmentioning

confidence: 97%

Raynaud's Phenomenon Caused by β‐Receptor Blocking Drugs

Eliasson

Danielson

Hylander

et al. 1984

Journal of Internal Medicine

View full text Add to dashboard Cite

show abstract

“…It is well absorbed, undergoes a 50% first pass loss and is eliminated by conjugation in the liver with a half-life of 3.5-4.5 h. Haemodynamically, it reduces blood pressure without reducing heart rate or cardiac output at rest. It is an effective antihypertensive agent and may have advantages over other P-blockers (71) though these have not been convincingly demonstrated and it has not yet become more popular than the P-blockers without a-blocking potential.…”

Section: Drugs With A-blocking U T I V 2 D a B E T A L O Lmentioning

confidence: 99%